Last Updated: November 16, 2026

Drug Sales Trends for ALPHAGAN P

« Back to Dashboard


Payment Methods and Pharmacy Types for ALPHAGAN P (2022)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $48,639,633
INSIDE ANOTHER STORE $3,580,613
[disabled in preview] $118,824,614
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 239,414
INSIDE ANOTHER STORE 23,663
[disabled in preview] 313,171
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICARE $110,565,133
PRIVATE INSURANCE $4,454,100
[disabled in preview] $62,817,641
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for ALPHAGAN P
Drug Units Sold Trends for ALPHAGAN P

Annual Sales Revenues and Units Sold for ALPHAGAN P

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
ALPHAGAN P ⤷  Start Trial ⤷  Start Trial 2022
ALPHAGAN P ⤷  Start Trial ⤷  Start Trial 2021
ALPHAGAN P ⤷  Start Trial ⤷  Start Trial 2020
ALPHAGAN P ⤷  Start Trial ⤷  Start Trial 2019
ALPHAGAN P ⤷  Start Trial ⤷  Start Trial 2018
ALPHAGAN P ⤷  Start Trial ⤷  Start Trial 2017
>Drug Name >Revenues (USD) >Units >Year

Alphagan P Market Analysis and Sales Projections

Last updated: September 2, 2026

Alphagan P is a brimonidine tartrate ophthalmic solution marketed for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product has largely lost its U.S. franchise value because brimonidine generics are widely available, core formulation protections have expired or become commercially ineffective, and payers generally favor lower-cost alternatives. Current commercial opportunity is concentrated in differentiated low-concentration formulations, preservative-tolerant patients, and markets where generic substitution is limited.

Standalone Alphagan P revenue is not separately disclosed by AbbVie. The projections below are therefore modeled estimates rather than reported company sales.

What is Alphagan P and how does it compete?

Alphagan P contains brimonidine tartrate, an alpha-2 adrenergic agonist. It reduces aqueous humor production and increases uveoscleral outflow. The product is used two to three times daily depending on the concentration and prescribing instructions.

Product Active ingredient Concentration Primary use Commercial status
Alphagan P Brimonidine tartrate 0.1% Glaucoma and ocular hypertension Branded product with generic competition
Alphagan P Brimonidine tartrate 0.15% Glaucoma and ocular hypertension Branded product with generic competition
Generic brimonidine Brimonidine tartrate 0.1%, 0.15%, 0.2% Glaucoma and ocular hypertension Broad generic availability
Timolol ophthalmic Timolol maleate 0.25%, 0.5% Glaucoma and ocular hypertension Mature generic market
Latanoprost Prostaglandin analog 0.005% Glaucoma and ocular hypertension Large generic market
Dorzolamide/timolol Fixed combination Multiple Glaucoma and ocular hypertension Generic and branded competition
Netarsudil Rho kinase inhibitor 0.02% Glaucoma and ocular hypertension Branded, newer mechanism
Bimatoprost Prostaglandin analog 0.01%, 0.03% Glaucoma and ocular hypertension Branded and generic competition

The main commercial distinction of Alphagan P is its Purite-preserved formulation. Purite is converted into naturally occurring components after instillation and was designed to improve ocular tolerability relative to older benzalkonium chloride-preserved products. The clinical benefit is most relevant for patients with ocular-surface disease or intolerance to conventional preservatives. FDA labeling identifies brimonidine tartrate ophthalmic solution as a treatment for elevated intraocular pressure in open-angle glaucoma and ocular hypertension.[1]

What is the FDA regulatory status of Alphagan P?

Alphagan P is an FDA-approved ophthalmic prescription product. The 0.15% formulation received FDA approval before the 0.1% formulation, which was introduced to provide a lower brimonidine concentration while maintaining pressure-lowering activity.

FDA regulatory characteristics include:

  • Prescription-only ophthalmic solution.
  • Small-molecule drug rather than a biologic.
  • No biosimilar pathway applies.
  • Generic applicants generally use an abbreviated new drug application, or ANDA.
  • Therapeutic equivalence depends on the approved generic product, concentration, dosage form, and FDA Orange Book designation.
  • Common adverse effects include allergic conjunctivitis, conjunctival hyperemia, dry mouth, and fatigue.[1]

Generic brimonidine products have entered the market in multiple strengths. The availability of generic products materially limits Alphagan P’s ability to preserve premium pricing.

What is the Orange Book status of Alphagan P?

The Orange Book historically listed patents and regulatory exclusivities associated with Alphagan P and related brimonidine formulations. The commercial relevance of those listings has declined as key protections expired and generic competition expanded.

Regulatory issue Alphagan P impact
Active ingredient patent Expired or commercially exhausted
Formulation protection Limited remaining blocking value in the U.S.
Method-of-use protection Narrow value because glaucoma treatment is established and generic labels cover common indications
Orange Book listing Historical listings may remain relevant to litigation records, but they do not prevent broad generic substitution
Pediatric exclusivity Not a current commercial barrier
New chemical entity exclusivity Expired
Biosimilar exposure None; brimonidine is a small molecule
ANDA competition High

A current Orange Book review should be performed against the exact NDA and strength because FDA listings can change through patent delisting, expiration, or product discontinuation updates.[2] The practical conclusion is unchanged: Alphagan P is a post-exclusivity brand facing generic substitution.

When did Alphagan P lose exclusivity?

Alphagan P lost effective market exclusivity after the expiration of its principal drug and formulation protections and the launch of generic brimonidine products. The exact timing differs by strength, formulation, patent challenge, and generic approval.

A simplified exclusivity timeline is:

Period Commercial event Market consequence
Initial launch period Allergan commercializes brimonidine products Branded pricing and ophthalmology promotion
Early formulation expansion Lower-concentration Alphagan P formulation introduced Differentiation based on tolerability and concentration
Patent challenge period Generic manufacturers pursue ANDA approvals and possible Paragraph IV certifications Litigation and launch uncertainty
Post-expiration period Generic brimonidine products enter or expand Rapid price erosion and payer substitution
Current market Brand remains available but competes against low-cost products Declining brand volume and limited pricing power

Which companies are challenging Alphagan P with generics?

The U.S. brimonidine market has included multiple generic ophthalmic manufacturers and suppliers. Depending on concentration and product availability, competitors have included large generic companies such as Teva, Sandoz, Apotex, Dr. Reddy’s Laboratories, Rising Pharmaceuticals, and other ANDA holders.

Generic competition is stronger for 0.2% brimonidine than for the branded Alphagan P concentrations because 0.2% products have been available for many years. Competition for 0.1% and 0.15% products also limits brand pricing because physicians and pharmacies can substitute among therapeutically similar brimonidine formulations.

What is the Paragraph IV risk?

Paragraph IV risk was most significant before the relevant Alphagan P patent protections expired. An ANDA applicant could certify that a listed patent was invalid, unenforceable, or not infringed. Such a certification could trigger Hatch-Waxman litigation and a 30-month stay of FDA approval in qualifying circumstances.[3]

That risk is now primarily historical for Alphagan P. Any remaining litigation would more likely involve:

  • A specific formulation patent.
  • A manufacturing process patent.
  • A narrow method-of-use claim.
  • Product-specific patent listing disputes.
  • Regulatory exclusivity or labeling issues.

A broad reversion to branded exclusivity is unlikely absent a new formulation or delivery technology.

What patents protect Alphagan P?

The historical Alphagan P estate focused on the following technical areas:

  1. Brimonidine ophthalmic formulations.
  2. Lower-concentration brimonidine solutions.
  3. Purite or oxidative preservative systems.
  4. Ocular tolerability and preservative performance.
  5. Methods for reducing intraocular pressure.
  6. Packaging, stability, and manufacturing characteristics.

The strongest historical differentiation was formulation-based rather than mechanism-based. Brimonidine itself is an established active ingredient, and the glaucoma indication is conventional. As a result, composition and preservative claims were more commercially important than broad method-of-use claims.

Current patent strength is best characterized as low for the legacy product and moderate for a new brimonidine formulation supported by fresh clinical or device claims. A new product could obtain protection around:

  • A novel preservative system.
  • A sustained-release insert or implant.
  • A lower-frequency delivery regimen.
  • A combination with another glaucoma drug.
  • A formulation that improves ocular-surface tolerability.
  • A device or container-closure system.

What formulations are protected by Alphagan P?

The commercial differentiation of Alphagan P is tied to its low-concentration formulations and Purite preservation system. These features can support product preference in patients who experience irritation from conventional preserved eye drops.

Formulation attribute Value to Alphagan P Generic erosion risk
Brimonidine tartrate active ingredient Provides pressure-lowering effect Very high
0.1% concentration Lower drug concentration and differentiated tolerability profile High
0.15% concentration Branded formulation differentiation High
Purite preservative Supports ocular-surface positioning Moderate to high
Multi-dose bottle Convenient and inexpensive High
Ophthalmic drop delivery Standard route Very high

A formulation patent may remain legally relevant after commercial exclusivity has weakened. Generic manufacturers can avoid infringement through alternative concentrations, preservatives, containers, or manufacturing processes. The practical value of any remaining claim therefore depends on claim scope, validity, enforceability, and whether the claim covers a commercially important product.

How large is the Alphagan P market?

The relevant market has three layers:

  1. The global prescription glaucoma market.
  2. The brimonidine segment.
  3. The branded Alphagan P segment.

The global glaucoma market includes prostaglandin analogs, beta blockers, carbonic anhydrase inhibitors, alpha-2 agonists, rho kinase inhibitors, and fixed combinations. Prostaglandin analogs generally lead first-line treatment because of once-daily dosing and strong pressure-lowering performance. Brimonidine is commonly used as adjunctive therapy or as an alternative when other classes are unsuitable.

Estimated U.S. market structure

Segment Estimated annual U.S. value, 2024 base case Growth profile
Total prescription glaucoma drops $3.0 billion-$4.5 billion Low-single-digit growth
Brimonidine-containing products $150 million-$275 million Flat to declining
Branded Alphagan P $25 million-$75 million Mid- to high-single-digit decline
Generic brimonidine $125 million-$225 million Stable volume, declining price

These are analytical estimates based on the maturity of the glaucoma market, generic availability, historical branded-generic substitution, and the absence of disclosed standalone Alphagan P sales. They should not be interpreted as reported AbbVie product revenue.

What are Alphagan P sales projections?

Base-case projection

The base case assumes continuing U.S. generic substitution, stable glaucoma prevalence, limited brand promotion, and no major product shortage.

Year Estimated Alphagan P U.S. sales Year-over-year change
2024 $45 million-$65 million Base year
2025 $41 million-$60 million -5% to -8%
2026 $37 million-$55 million -6% to -8%
2027 $34 million-$51 million -5% to -8%
2028 $31 million-$48 million -5% to -7%
2029 $29 million-$45 million -4% to -7%

The implied 2024-2029 compound annual decline is approximately 5% to 7%.

Scenario analysis

Scenario 2029 U.S. Alphagan P sales Assumptions
Downside $15 million-$25 million Increased generic substitution, weaker formulary coverage, reduced brand availability
Base case $29 million-$45 million Gradual brand erosion and stable patient demand
Upside $55 million-$85 million Generic supply disruption, improved brand contracting, or new tolerability-focused promotion

The upside case is temporary unless supported by a new clinical, delivery, or reimbursement advantage. A sustained return to historical branded pricing is unlikely in a mature generic market.

How does Alphagan P compare with competing glaucoma drugs?

Drug class Main commercial advantage Main weakness versus Alphagan P
Latanoprost and other prostaglandins Once-daily dosing and strong first-line positioning Ocular hyperemia and class-specific tolerability issues
Timolol Low price and long clinical history Cardiovascular and pulmonary contraindications
Dorzolamide/timolol Fixed-combination convenience More frequent dosing and tolerability concerns
Brimonidine Useful adjunctive pressure lowering and alternative mechanism Three-times-daily dosing, allergy risk, generic price erosion
Netarsudil Newer mechanism and differentiated clinical positioning High branded price and hyperemia
Bimatoprost Strong pressure lowering Higher hyperemia and eyelash-related effects in some patients

Alphagan P’s strongest competitive position is in patients who require add-on therapy and cannot tolerate beta blockers or certain prostaglandin regimens. Its weakest position is routine first-line treatment where generic latanoprost or timolol is preferred.

What generic launch risks exist for Alphagan P?

Generic entry risk is already realized rather than prospective. The principal remaining risks are commercial:

  • Additional ANDA approvals for 0.1% or 0.15% products.
  • Pharmacy-level substitution.
  • Formulary exclusion or higher patient copay tiers.
  • Generic price reductions.
  • Wholesaler delisting.
  • Manufacturing interruptions that affect either brand or generic supply.
  • Prescriber migration toward once-daily prostaglandin analogs.
  • Reduced physician promotion by the brand owner.

A shortage affecting generic suppliers could temporarily lift Alphagan P demand. That effect would likely be episodic and would not establish durable pricing power.

What licensing deals and litigation affect Alphagan P?

Alphagan P originated in Allergan’s ophthalmology portfolio. AbbVie completed its acquisition of Allergan in 2020, transferring Allergan’s ophthalmic products, including Alphagan P, into AbbVie’s commercial portfolio.[4]

No current major licensing transaction or active high-value patent dispute is broadly associated with Alphagan P’s commercial outlook. Historical Hatch-Waxman disputes and generic-entry proceedings remain relevant to the product’s exclusivity history, but the present investment issue is generic erosion rather than litigation-driven launch uncertainty.

How strong is the Alphagan P patent estate?

Factor Assessment
Active-ingredient protection Weak or expired
Broad glaucoma method claims Weak
Legacy formulation claims Limited residual value
Preservative-based differentiation Historically important; current blocking power limited
Manufacturing patents Potentially relevant but unlikely to protect the entire market
New product extension opportunity Moderate if supported by a novel formulation or delivery system
Litigation leverage Low for the legacy product
Generic entry barrier Low

The legacy estate has low strategic strength. A lifecycle-management program could create stronger protection, but it would need a meaningful clinical or administration advantage rather than a minor concentration change.

What is the commercial outlook for Alphagan P?

Alphagan P is likely to remain a niche branded glaucoma product with declining U.S. sales. Demand will persist because brimonidine is clinically useful, but most of that demand will be captured by generic manufacturers. The brand can retain value through:

  • Ocular-surface tolerability positioning.
  • Patients with documented intolerance to generic preservatives.
  • Physician preference for the branded formulation.
  • International markets with slower generic penetration.
  • Contracting arrangements with insurers or specialty distributors.
  • Combination-product development.

The core product does not have the profile of a high-growth pharmaceutical asset. Its economic value is closer to a mature specialty brand with residual cash flow than to a protected innovation asset.

Key Takeaways

  • Alphagan P is a brimonidine tartrate ophthalmic solution for glaucoma and ocular hypertension.
  • AbbVie does not separately disclose Alphagan P revenue.
  • Estimated U.S. branded sales are approximately $45 million-$65 million in 2024.
  • Base-case sales decline to approximately $29 million-$45 million by 2029.
  • Generic brimonidine creates the primary commercial threat.
  • Biosimilar risk does not apply because brimonidine is a small-molecule drug.
  • Legacy formulation and method-of-use protections have limited current blocking value.
  • The most valuable remaining differentiation is Purite preservation and perceived ocular tolerability.
  • Long-term upside depends on a new delivery system, combination product, or clinically differentiated formulation.
  • Alphagan P is a declining mature brand, not a near-term exclusivity-growth asset.

FAQs

Is Alphagan P still under patent protection?

Any remaining patent listings must be reviewed in the current FDA Orange Book for the relevant strength and NDA. Commercially meaningful exclusivity has largely ended because generic brimonidine products are widely available.

Is generic brimonidine as effective as Alphagan P?

FDA-approved generic brimonidine products must meet applicable quality, bioequivalence, and performance requirements. Physicians may still select Alphagan P for individual patients based on tolerability, preservative preference, or clinical response.

Does Alphagan P have biosimilar competition?

No. Biosimilars apply to biological products. Alphagan P contains the small molecule brimonidine tartrate and competes through the generic drug pathway.

Can Alphagan P sales increase during a generic brimonidine shortage?

Yes. A temporary generic supply disruption could shift prescriptions toward Alphagan P. The effect would likely reverse when generic supply normalizes.

What would make Alphagan P commercially attractive again?

A sustained recovery would require a differentiated product, such as once-daily delivery, improved ocular-surface tolerability, a long-acting formulation, a fixed-dose combination, or reimbursement that materially reduces the brand-versus-generic price gap.

References

  1. U.S. Food and Drug Administration. (2024). Alphagan P prescribing information.
  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and Paragraph IV certifications.
  4. AbbVie Inc. (2020). Annual report for fiscal year 2020.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.